Nabriva -- Facing Difficult Times -- Relinquishes the Exclusive Right to Sell Sivextro® in the US, Returns It To Merck...

In truth, this "to-and-fro" is a very common occurrence in the life cycle of any stable, longer term drug. In this case, it is a drug used to combat so-called Gram-positive microorganisms, typically in the hospital settings. And now, Merck itself, or perhaps with several others (which may include Nabriva, but on a non-exclusive basis, in the US) will distribute the medicine. [Just one of many 2015 era background pieces of mine, on the Cubist acquisition.]

Nabriva had acquired the exclusive US rights in 2020, and in the process, let go of most of its R&D staff, deciding to focus on near term commercial revenue opportunities. But it now seems that Nabriva simply wasn't selling enough of the drug, under the Merck performance metrics, in those 2020 contracts. [Nabriva had previously reported about $24.5 million in net revenue from sales of the drug through the first three quarters of 2022 -- clearly a fly-speck, to Merck.] So it is "a free-ball", once again. Here's the latest:

. . .Pursuant to the Letter Agreement, the Company's exclusive license to promote, distribute and commercialize SIVEXTRO was converted to a non-exclusive license, and the parties agreed to terminate the Distribution Agreement, effective June 30, 2023.

The Company no longer intends to actively promote Sivextro but expects to continue to make Sivextro available to wholesale customers and record revenue on account of any sales until June 30, 2023. After June 30, 2023, the Company will no longer have the right to promote, distribute or commercialize [the drug in the US]. . . .

Now you know. . . and onward, as we look forward to a long in coming weekend, with the baby girls, and lots of giggles. . . smile. . . .

नमस्ते